Evidence map›Paper›PMID 40678197›Full record

ArticleBrain, behavior, & immunity - health2025

Frequency of autoimmune-associated exogenous psychoses in routine clinical care.

Maria Buthut, David Haslacher, Surjo R Soekadar, Felix Machleid, Jakob Kaminski, Philipp Reber, Johanna Schoener, Anna Pichler, Moritz Thiele, Jochen Michely and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain, behavior, & immunity - health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Maria ButhutDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
David HaslacherDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Surjo R SoekadarDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Felix MachleidBerlin Institute of Health at Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Jakob KaminskiDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Philipp ReberDepartment of Psychology, University of California, Berkeley, CA, USA.
Johanna SchoenerDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Anna PichlerDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Moritz ThieleDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Jochen MichelyDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Helle Foverskov-RasmussenDepartment of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany.
Irina BaskowDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Verena Rösgen-PetzoldDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Harald PrüssDepartment of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany.
Matthias EndresDepartment of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany.
Lasse BrandtDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Andreas HeinzDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Psychosis occurs in a wide spectrum of mental and somatic disorders, with autoimmune processes being a potentially underdiagnosed cause. Clinical warning-signs can help identifying autoimmune encephalitis (AIE) or psychosis (AIP). Here we evaluated warning-signs and biomarkers in patients experiencing acute psychotic episodes who were admitted to inner-city sectorized care with a focus on identifying autoimmune causes of psychosis. Methods: We analyzed data obtained from routine clinical care, including blood, urine, CSF, EEG, and MRI when available. CSF-analysis included screening for antineuronal autoantibodies using commercial antibody screening (CAS) and indirect immunofluorescence (IFT). Origin of psychosis was defined according to patients' discharge diagnosis (ICD-10 criteria). Results: Within 39 months, 352 participants were included, 114 of them experienced their first episode of psychosis (FEP). In 139 patients, psychotic symptoms were attributed to exogenous origin (F0: N = 90; F1: N = 48), the others were diagnosed with categories F2, F3 and F4. Among the 139 patients, 3 patients had pleocytosis or other CSF abnormalities. CAS was positive in two patients in CSF, leading to a confirmed diagnose of AIP in only one case while evaluated as unspecific in the other. IFT determined the prevalence of IgG-autoantibodies in CSF in four patients, who had FEP. Symptoms improved following immunotherapy in three of the four diagnosed patients. Conclusion: CSF analysis suggested four cases with AIP, with only one detected through commercial assays. Despite the rather low prevalence of AIP in this community sample, the availability of specific treatment options underscores the importance of further research regarding in-depth diagnostic evaluation for autoimmune processes in patients with acute psychosis.

Identifiers

PMID40678197
PMCPMC12267999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.